This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Accenture announced it has made a strategic investment, through Accenture Ventures , in QuantHealth , an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients. Petra Jantzer, Ph.D.,
23andMe tried to monetize its extensive genetic database by collaborating with pharmaceutical companies for drug research. While promising, drugdevelopment requires significant time and investment, delaying any financial returns and impacting the company’s short-term revenue.
In the fast-paced realm of pharmaceuticals, where innovation can mean the difference between life and death, the integration of artificial intelligence (AI) is reshaping the landscape of drug discovery and development. The marriage of AI and pharmaceuticals holds immense promise, particularly in the realm of drug discovery.
The FDA issued a series of four patient-focused drugdevelopment (PFDD) guidance documents which outline how patient co-design needs to successfully happen. After all of this time and energy expended, it’s only right that patients would be witness to accountability of pharma/biotech to incorporate our collective voice.
It is key for pharmaceutical companies to recognize that efficiency does not override compliance, patient safety or regulatory standards. Jane Reed, Director of Life Sciences at Linguamatics, an IQVIA company Pharmaceuticaldevelopers have always prioritized drug safety. Dave Latshaw, CEO at BioPhy 1.
Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. The same definition of patient engagement applies to industry, except that the interventions lead to more human centered design and value-based care.
This ML-driven adaptive process can significantly accelerate the clinical drugdevelopment process and increase certainty along the way, resulting in more efficient, targeted, and ultimately more successful clinical trials. Oramed Pharmaceuticals Inc., bringing new needed treatments to patients.”
QuantHealth bridges these gaps by simulating trials at scale, to expedite, derisk, and optimize drugdevelopment. QuantHealth proudly supports several large pharma companies, numerous biotechs, as well as CROs, and other industry partners.
Indivi is dedicated to unlocking the immense potential of digital biomarkers in drugdevelopment and healthcare by creating a unique symbiotic intersection between expert knowledge in Data Science, Clinical Science and Advanced Analytics (including machine learning and artificial intelligence).
These individuals have personally built leading technology platforms supercharging drugdevelopment globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,
As a leader in patient advocacy, I am often asked to speak on the topic of patient centricity and patient advocacy from the biotech/pharma perspective. Meaningfully incorporating this insight in all areas of our work must be the cornerstone of participatory medicine for drugdevelopment and access. Did you enjoy this post?
million from Capital Grand Est and MACSF, as well as business angels, to accelerate its development in Europe and the United States. STRASBOURG, France–(BUSINESS WIRE)– BrainTale, a French medtech deciphering white matter to enable better brain care, announces it has gathered € 4.5 Today, the company has gathered €4.5
About Automera Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation. Since our inception in 2022, ClavystBio has committed over US$220m to biotech, diagnostics, and digital health companies, as well as early-stage VC funds.
Both Wellington and Forbion are visionaries and highly experienced biotech investors, and we look forward to working closely with them in our efforts to transform the gene editing landscape.” “Our Forbion invests in life sciences companies that are active in the (bio) pharmaceutical space. Forbion manages well over EUR 2.3
Existing investors include biotech giant Celgene Corp. , and pharmaceutical entrepreneur Robert Duggan. February 2015: Dr. But key facets of its business didn’t develop as planned, say people familiar with the company. DNA-sequencing company Illumina Inc.,
This is not sustainable when so many of the active pharmaceutical ingredients and medical device components we rely on come from a small handful of countries. This could be a breakthrough for the pharmaceutical industry. Lauren Ohlsson, Lead of Industry Solutions – Pharmaceuticals & Healthcare at VDX.tv.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content